Allergan PLC. (AGN) Given New $191.00 Price Target at Cantor Fitzgerald

Allergan PLC. (NYSE:AGN) had its price objective dropped by stock analysts at Cantor Fitzgerald to $191.00 in a research report issued on Thursday. The firm currently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 7.77% from the stock’s previous close.

A number of other research firms also recently weighed in on AGN. Royal Bank Of Canada dropped their target price on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating for the company in a research report on Thursday. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $245.00 price target (down from $258.00) on shares of Allergan PLC. in a research note on Thursday. UBS AG reaffirmed an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 9th. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Argus reaffirmed a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company. Allergan PLC. presently has a consensus rating of “Hold” and an average target price of $248.20.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $3.32 EPS.

Allergan PLC. announced that its board has approved a stock buyback program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/02/allergan-plc-agn-given-new-191-00-price-target-at-cantor-fitzgerald.html.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Allergan PLC. by 2.2% in the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after purchasing an additional 482,220 shares in the last quarter. Northern Trust Corp grew its position in shares of Allergan PLC. by 8.8% in the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock valued at $1,092,189,000 after purchasing an additional 364,722 shares in the last quarter. Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. in the first quarter valued at approximately $761,339,000. Edgewood Management LLC grew its position in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after purchasing an additional 178,055 shares in the last quarter. Finally, Epoch Investment Partners Inc. grew its position in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after purchasing an additional 73,081 shares in the last quarter. Institutional investors own 82.02% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply